Modern Approaches to an Initial and Anti-Relapse Treatment of Gastroesophageal Reflux Disease
The article deals with the modern approaches to an initial and anti-relapse treatment of gastroesophageal reflux disease (GERD), based on the recommendations of the last two American consensus. According to these data, the main drugs for the treatment of GERD are proton pump inhibitors (PPIs), which are divided into the first- and second-generation drugs and can be used in standard doses, as well as in double- and half-doses. Second-generation drugs are more effective and safe as they less dependent on CYP2C19 polymorphism of. It is concluded that in most cases, the initial treatment should begin with the use of standard or double-doses of PPI, and supporting one — with standard or half-doses used for a variety of schemes — constant, intermittent or therapy «on demand». The best preparation for a long-term treatment of GERD, especially if it is necessary to take other drugs, is pantoprazole.
Full Text:PDF (Русский)
Bekkers C.H., Touw D.J., Lamers C.B., Geus W.P. The effect of CYP2C19 polymorphism on the pharmacokinetics and acid-inhibitory effects of oral lansoprazole and omeprazole // Br. J. Clin. Pharmacol. — 2002. — 54(5). — 553.
Donnellan C., Sharma N., Preston C., Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease [Systematic Review] // Cochrane Database of Systematic Reviews. — 2005. — 3. — 3.
Fitton A., Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders // Drugs. — 1996. — 51(3). — 460-482.
Furuta T., Sugimoto M., Shirai N., Ishizaki T. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor // Pharmacogenomics. — 2007. — 8. — 1199-1210.
Gerson L.B., Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach // Eur. J. Gastroenterol. Hepatol. — 2001. — 13(5). — 611-616.
Hagymási K., Müllner K., Herszényi L., Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors // Pharmacogenomics. — 2011. — 12(6). — 873-888.
Kahrilas P.J., Shaheen N.J., Vaezi M.F. et al. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease // Gastroentero-logy. — 2008. — 135. — 1383-1391.
Katz P.O., Gerson L.B., Vela M.F. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease // The American Journal of Gastroenterology. — March 2013. — Vol. 108. — Р. 308-328.
Kromer W. Similarities and Differences in the Properties of Substituted Benzimidazoles: A Comparison detween Pantoprazole and Related Compounds // Digestion. — 1995. — 56. — 443-454.
Li X.-Q., Andersson T.B., Ahlstrom M., Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities // Drug. Metab. Dis. — 2004. — 32(8). — 821-827.
McNamara D. Gastro-oesophageal reflux disease and ulcer disease in Europe // The Burden of Gastrointestinal Diseases in Europe. — 2004. — 31-36.
Miner P.B. Jr, Katz P.O., Chen Y., Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study // Am. J. Gastroenterol. — 2003. — 98. — 2616-2620.
Mullin J.M., Gabello M., Murray L.J. et al. Proton pump inhbitors: actions and reactions // Drug. Disc. Today. — 2009. — 14(13–14). — 647-660.
Ogawa R., Echizen H. Drug-drug interaction profiles of proton pump inhibitors // Clin. Pharmacokinet. — 2010. — 49(8). — 509-533.
Pace F., Tonini M., Pallotta S. et al. Systematic review: maintenance treatment of gastrooesophageal reflux disease with proton pump inhibitors taken ‘on-demand’ // Aliment Pharmacol. Ther. — 2007. — 26. — 195-204.
Richter J. The refractory GERD patient // World Gastroenterol. News. — 2007. — Vol. 12. — 11-13.
Sachs G., Shin J. Differential reversal of inhibition of gastric H/K-ATPase following pantoprazole or omeprazole administration // Am. J. Gzstroenterol. — 2001. — 96. — S71. — Abstr. 223.
Steinijans V., Huber R., Hartmann M. et al. Lack of pantoprazole drug interactions in man: an updated review // Int. J. Clin. Pharmacol. Ther. — 1996. — 34(1 Suppl.). — S31-S50.
Tanaka M., Ohkubo T., Otani K. et al. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin // Clin. Pharmacol. Ther. — 2001. — 69(3). — 108-113.
- There are currently no refbacks.
Copyright (c) 2016 GASTROENTEROLOGY
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2018